Unaudited Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Revenue:
Revenues	$ 38,464,000	$ 32,843,000	$ 106,869,000	$ 91,968,000
Expenses:
Cost of revenue (excluding depreciation and amortization)	6,472,000	4,388,000	16,477,000	12,594,000
Payment processing expense	7,530,000	6,902,000	21,125,000	20,952,000
Sales and marketing	10,481,000	8,348,000	30,013,000	24,170,000
Research and development	5,732,000	4,774,000	16,267,000	13,762,000
General and administrative	10,370,000	7,184,000	28,721,000	20,849,000
Depreciation	2,447,000	2,153,000	7,125,000	6,444,000
Amortization	1,546,000	1,325,000	4,531,000	3,823,000
Total expenses	44,578,000	35,074,000	124,259,000	102,594,000
Operating loss	(6,114,000)	(2,231,000)	(17,390,000)	(10,626,000)
Other income (expense)	62,000	77,000	(229,000)	(740,000)
Change in fair value of warrant liability	0	0	0	(3,307,000)
Interest income (expense)	(467,000)	(219,000)	(1,206,000)	(1,769,000)
Total other income (expense)	(405,000)	(142,000)	(1,435,000)	(5,816,000)
Loss before provision for income taxes	(6,519,000)	(2,373,000)	(18,825,000)	(16,442,000)
Provision for income taxes	(194,000)	(64,000)	(371,000)	(183,000)
Net loss	(6,713,000)	(2,437,000)	(19,196,000)	(16,625,000)
Preferred stock dividend paid	0	0	0	(14,955,000)
Accretion of redeemable preferred stock	0	0	0	(56,175,000)
Net loss attributable to common stockholders, basic and diluted	$ (6,713,000)	$ (2,437,000)	$ (19,196,000)	$ (87,755,000)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.17)	$ (0.07)	$ (0.51)	$ (5.85)
Weighted-average common shares outstanding, basic and diluted (in shares)	38,511,370	35,790,951	37,855,503	15,007,247
Subscription and related services
Revenue:
Revenues	$ 17,468,000	$ 14,606,000	$ 50,196,000	$ 41,292,000
Payment processing fees
Revenue:
Revenues	12,917,000	11,559,000	36,452,000	34,781,000
Life sciences
Revenue:
Revenues	$ 8,079,000	$ 6,678,000	$ 20,221,000	$ 15,895,000